Company Focus
Galderma
Latest Galderma News
Biotechnology
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
Dermatology News
Insights
Company Spotlight
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.
Latest News & Features of interest to Galderma
Biotechnology
The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Amtagvi (lifileucel) suspension for intravenous infusion, submitted by US biotech Iovance Biotherapeutics. 19 February 2024
Biotechnology
The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. 16 February 2024
Pharmaceutical
San Diego, USA-based precision oncology company Erasca announced two clinical trial collaboration and supply agreements (CTCSAs) with Swiss pharma giant Novartis for the MEK inhibitor Mekinist (trametinib). 15 February 2024
Biotechnology
French pharma major Sanofi is angry that its interleukin (IL)-13 and IL-4 blocking antibody Dupixent (dupilumab) has been recommended for the treatment of moderate-to-severe prurigo nodularis (PN) in Scotland but not in England and Wales. 14 February 2024
Biotechnology
Immuno-dermatology company Alys Pharmaceuticals has launched with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by healthcare-focused investment firm Medicxi. 12 February 2024
Biotechnology
Belgian drugmaker UCB is closing in on another approval with its monoclonal IgG1 antibody, bimekizumab. 9 February 2024
Pharmaceutical
US pharma major Eli Lilly posted its fourth-quarter and full-year financial results on Tuesday. 6 February 2024
Pharmaceutical
American dermatology company Verrica Pharmaceuticals has filed a lawsuit against Canada’s Dormer Laboratories related to the active ingredient cantharidin. 5 February 2024
Biotechnology
Regeneron Pharmaceuticals’ shares were up 2.2% at $951.66 pre-market today, after it announced financial results for the fourth quarter and full year 2023. 2 February 2024
Biotechnology
Chinese biopharma Hutchmed today announced that Hong Kong-based Inmagene Biopharmaceuticals has exercised options to license two drug candidates discovered by Hutchmed. 2 February 2024
Latest In Brief for Galderma
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Latest Dermatology Ones To Watch News
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
18 September 2024
13 August 2024
24 July 2024
17 May 2024
Dermatology Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze